Johnson & Johnson reportedly wants to sell Cerenovus for 1B
Published on February 18, 2025
According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars. The company is said to be exploring options to divest this division as part of its ongoing restructuring efforts. Cerenovus, which focuses on developing innovative stroke care solutions, has not performed as well as expected in recent years. This potential sale aims to allow Johnson & Johnson to streamline its operations and focus on more profitable areas of the healthcare sector. Industry experts believe that a sale of this magnitude could attract significant interest from potential buyers looking to expand their presence in the stroke care market. Investors are advised to consult professionals from Stocks Prognosis for a forecast on the future movement of Johnson & Johnson's stocks.
Investor opinions & comments
To leave a comment, you need to Login or Register.
WealthyWalter
February 21, 2025 at 17:42
This sale could create an opportunity for another company to acquire innovative stroke care solutions and make advancements in the field
SavvySusan
February 21, 2025 at 15:22
I'm excited to see what other areas Johnson & Johnson will focus on after divesting Cerenovus. It could lead to new and exciting developments in the healthcare sector
StockSteve
February 21, 2025 at 11:48
This sale could lead to increased competition in the stroke care market, benefiting patients and driving innovation in the industry
EliWells
February 21, 2025 at 03:31
I'm not sure if selling Cerenovus is the best solution for Johnson & Johnson. They should consider investing in improving the performance of the division instead
MikeWilliams
February 20, 2025 at 23:42
Is the $1 billion price tag for Cerenovus justified? It seems like a high amount for a division that hasn't met expectations
EliWells
February 20, 2025 at 12:17
Johnson & Johnson's decision to sell Cerenovus could help them streamline their operations and improve profitability in the healthcare sector
CharlesScott
February 20, 2025 at 07:38
Johnson & Johnson's restructuring efforts show their commitment to adapt and optimize their operations according to market demands
NoraJenkins
February 19, 2025 at 10:52
What if Cerenovus starts performing better in the future? Selling it now could lead to missed opportunities and potential regrets
GraceStewart
February 19, 2025 at 03:15
This sale could be a great opportunity for Johnson & Johnson to refocus its efforts on more profitable areas
MarketMolly
February 18, 2025 at 22:28
I'm curious to know how this sale will impact Johnson & Johnson's stock prices in the coming months
CapitalChris
February 18, 2025 at 17:56
I wonder if Johnson & Johnson has already received any offers for Cerenovus. It would be interesting to see the potential buyers lining up
JamesThomas
February 18, 2025 at 06:39
It's interesting to see how potential buyers will respond to the sale and if they see value in expanding their presence in the stroke care market